The ARCHIMEDlife Dual Strategy: From routine laboratory services to the development, validation and certification of project-specific diagnostic assays. We offer you the full range of diagnostic support with our state-of-the-art equipped laboratories from Clinical Mass Spectrometry to Next-Generation Sequencing. We make novel laboratory tests and biomarkers accessible for patients.
Stay in touch with us and receive the latest information on time. Please register for our monthly ARCHIMEDlife newsletter.
We support pharmaceutical and biotech companies in performing comprehensive (international) diagnostic services particularly in the area of rare disorders and once novel treatments are available, to raise disease awareness across borders.
We offer the set-up of all relevant processes and infrastructure from logistics, legal and marketing, to comprehensive laboratory analysis and medical reporting. Fast, reliable and high-quality services combined with cutting-edge laboratory technologies from Clinical Mass Spectrometry to Next-Generation Sequencing.
We are already providing services to thousands of physicians in more than 60 countries with all required processes implemented. Just contact us to get in touch with our unique services for your diagnostic initiative: email@example.com
Every day we learn more and more on the nature of diseases. We work hand in hand with international medical and scientific experts in the discovery of new supportive biomarkers or improve existing laboratory tests using innovative technologies. Our experts in the research division are working in several global projects on the identification and evaluation of novel biomarkers in different medical fields with cutting edge technologies.
Our goal is to make biomarkers accessible for patients. Physicians and their patients shall benefit from additional supportive biomarkers for better diagnosis and/or disease monitoring. ARCHIMEDlife´s Dual Strategy is to develop biomarker tests that can be used for diagnostic purposes. Beneficial biomarker tests shall not stay on a research level. Our Development Division (ISO 13485 certified) has all requirements and expertise to validate and certify biomarker tests to make them accessible for patients in a daily routine laboratory.
Successful story of a biomarker: Visit our “Research Institute” section and take a look on our Publications, and see how a biomarker testing has changed the primary diagnostics particularly for identifying woman at risk with Fabry disease.
Please contact us at firstname.lastname@example.org to discuss your ideas and how to work together to progress the opportunities available.
Novel biomarker or an innovative diagnostic test on the horizon but still on “research use only” (RUO) level and not validated?
Our Development Division is fully ISO 13485 certified, and we have all necessary regulatory and legal processes in place to validate, certify, register and release any diagnostic assay for the in-vitro diagnostic (IVD) market, or use it in our highly-specialized clinical routine laboratories for your diagnostic project.
The diagnostic market is changing with personalized medicine and novel treatments that become available for e.g. rare disorders or in oncology. So, innovative and better diagnostic assays are needed to characterize patients and their disease, or to monitor progression of disease without or under treatment.
Please contact us at email@example.com to evaluate together the diagnostic tests you need in your project, and how to improve patient’s life.
We offer hiqh-quality services with our strong experience for Clinical Studies and Academic Research.
Our team is well experienced in both biochemistry and genetics applied in medical studies and research projects. Our laboratory is equipped with state-of-the-art technologies from Clinical Mass Spectrometry to Next-Generation Sequencing including qualified instruments, and our highly-experienced team will support you from planning to execution of your study.
We provide clinical services including:
Diagnostics ・Clinical Studies・Development
on 15 Mar, 2020
We stay open for you and your patients! We used the last days to prepare us to continue our work and services on the highest safety and responsibility. Please communicate this to...Read More
on 18 Feb, 2020
Fabry disease, an X-linked inherited lysosomal storage disorder, can be overlooked in heterozygous females due to random X-inactivation. In a pilot study, we investigated the combined strategy of measuring the biomarker, Lyso-globotriaosylceramide...Read More
on 17 Jan, 2020
ARCHIMEDlife is very proud to announce the strategic alliance with amedes Holding GmbH, a leading provider in interdisciplinary and medical-diagnostic services for patients, physicians and hospitals. Together, we will expand and continue...Read More
on 25 Sep, 2019
Combining high-quality biochemical testing with innovative genetic testing forms a powerful tool for personalized medicine, clinical research and diagnostics in rare diseases. ARCHIMEDlife Medical Laboratory, based in Vienna, provides biochemical and genetic...Read More
on 14 Mar, 2018
Our awarded work (Poster Finalist at MSACL Europe, also see the PDF Poster Hemoglobinopathies_MSACL) on hemoglobinopathies and thalassemias is now starting into a prospective study in cooperation with the University Medical Center Hamburg-Eppendorf,...Read More
on 07 Mar, 2018
Introduction: Methods: Results: Conclusion: Authors / corresponding author* JAlbinaNowakaSarah H.HailebDavid C.KaspercThomas P.MechtlercAndreas J.FlammeraPierre A.KrayenbuehldDaniel P.Franzena University Hospital Zurich, Zurich, Switzerland b University Zurich, Zurich, Switzerland c ARCHIMED Life Science, Vienna, Austria...Read More
on 07 Mar, 2018
The parallel measurement of lyso-GL-3 (lyso-Gb3) for Fabry disease is of high importance particularly for potential female Fabry patients, otherwise women at risk might be missed and consequently be undiagnosed. We analyzed...Read More
on 21 Nov, 2017
The 21st of November 2017 is ARCHIMEDlife´s 5th anniversary, a proof that out of an idea you can evolve a successful company with dedicated people and ongoing improvement. It is time to...Read More
on 13 Nov, 2017
Introduction: Diagnosis of neonatal sepsis remains a major challenge in neonatology. Most molecularbased methods are not customized for neonatal requirements. The aim of the present study was to assess the diagnostic accuracy...Read More